Log in

Analysts Hate These 12 Stocks in 2020 - 1 of 12

 
Biogen (NASDAQ:BIIB)

Number of Downgrades: 20 (in the last 90 days)
Consensus Rating: Hold
Rating Score: 2.2
Ratings Breakdown: 13 Buy Ratings, 15 Hold Ratings, 5 Sell Ratings.
Consensus Price Target: $305.90 (25.5% Upside)

Biogen logoBiogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases worldwide. The company offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for the treatment of spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. Read More 

Recent Recommendations for Biogen:

  • Biogen Inc. (NASDAQ: BIIB) had its price target raised by analysts at Royal Bank of Canada from $244.00 to $249.00. They now have a "sector perform" rating on the stock. (11/19/2020)
  • Biogen Inc. (NASDAQ: BIIB) was downgraded by analysts at TheStreet from a "b" rating to a "c+" rating. (11/11/2020)
  • Biogen Inc. (NASDAQ: BIIB) was downgraded by analysts at Truist to a "buy" rating. They now have a $443.00 price target on the stock, up previously from $310.00. (11/10/2020)
  • Biogen Inc. (NASDAQ: BIIB) was upgraded by analysts at DZ Bank AG from a "hold" rating to a "buy" rating. They now have a $265.00 price target on the stock. (11/10/2020)
  • Biogen Inc. (NASDAQ: BIIB) had its price target lowered by analysts at Royal Bank of Canada from $263.00 to $244.00. They now have a "sector perform" rating on the stock. (11/9/2020)
  • Biogen Inc. (NASDAQ: BIIB) had its price target lowered by analysts at Oppenheimer Holdings Inc. from $370.00 to $330.00. They now have an "outperform" rating on the stock. (11/9/2020)
  • Biogen Inc. (NASDAQ: BIIB) had its price target lowered by analysts at Mizuho from $282.00 to $244.00. They now have a "neutral" rating on the stock. (11/9/2020)
  • Biogen Inc. (NASDAQ: BIIB) had its price target lowered by analysts at HC Wainwright from $318.00 to $289.00. They now have a "buy" rating on the stock. (11/9/2020)
  • Biogen Inc. (NASDAQ: BIIB) was downgraded by analysts at Cowen Inc from an "outperform" rating to a "market perform" rating. They now have a $215.00 price target on the stock, down previously from $275.00. (11/9/2020)
  • Biogen Inc. (NASDAQ: BIIB) was downgraded by analysts at Bank of America Co. from a "neutral" rating to an "underperform" rating. They now have a $240.00 price target on the stock. (11/9/2020)






Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.